Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Apostolia Maria Tsimberidou; Tracey Waddelow; Hagop M. Kantarjian; Maher Albitar; Francis J. Giles

doi:10.1016/S0145-2126(02)00082-6

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Apostolia Maria Tsimberidou, Tracey Waddelow, Hagop M. Kantarjian, Maher Albitar, Francis J. Giles

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

Original language	English (US)
Pages (from-to)	375-380
Number of pages	6
Journal	Leukemia Research
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/S0145-2126(02)00082-6
State	Published - May 1 2003

Keywords

Enbrel
Multiple myeloma
Refractory
TNFα

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S0145-2126(02)00082-6

Fingerprint

Dive into the research topics of 'Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment'. Together they form a unique fingerprint.

Cite this

Tsimberidou, A. M., Waddelow, T., Kantarjian, H. M., Albitar, M., & Giles, F. J. (2003). Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment. Leukemia Research, 27(5), 375-380. https://doi.org/10.1016/S0145-2126(02)00082-6

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment. / Tsimberidou, Apostolia Maria; Waddelow, Tracey; Kantarjian, Hagop M. et al.
In: Leukemia Research, Vol. 27, No. 5, 01.05.2003, p. 375-380.

Research output: Contribution to journal › Article › peer-review

Tsimberidou, AM, Waddelow, T, Kantarjian, HM, Albitar, M & Giles, FJ 2003, 'Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment', Leukemia Research, vol. 27, no. 5, pp. 375-380. https://doi.org/10.1016/S0145-2126(02)00082-6

@article{ee43f81dabe547bb956655c649c89305,

title = "Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment",

abstract = "Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.",

keywords = "Enbrel, Multiple myeloma, Refractory, TNFα",

author = "Tsimberidou, {Apostolia Maria} and Tracey Waddelow and Kantarjian, {Hagop M.} and Maher Albitar and Giles, {Francis J.}",

year = "2003",

month = may,

day = "1",

doi = "10.1016/S0145-2126(02)00082-6",

language = "English (US)",

volume = "27",

pages = "375--380",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma

T2 - Increase in plasma TNFα levels during treatment

AU - Tsimberidou, Apostolia Maria

AU - Waddelow, Tracey

AU - Kantarjian, Hagop M.

AU - Albitar, Maher

AU - Giles, Francis J.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

AB - Elevated tumor necrosis factor (TNF)-α levels are associated with poor prognosis in patients with multiple myeloma (MM). Enbrel is a TNF antagonist fusion protein consisting of the extracellular, ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of human IgG1. Ten patients with refractory MM were treated with Enbrel 25mg s.c twice weekly for a minimum of eight median age was 63 years (range, 43-76). The total number of Enbrel doses was 191 (median 16; range, 3-55). TNFα plasma levels increased significantly during treatment with Enbrel. No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study.

KW - Enbrel

KW - Multiple myeloma

KW - Refractory

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=0037400526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037400526&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(02)00082-6

DO - 10.1016/S0145-2126(02)00082-6

M3 - Article

C2 - 12620287

AN - SCOPUS:0037400526

SN - 0145-2126

VL - 27

SP - 375

EP - 380

JO - Leukemia Research

JF - Leukemia Research

IS - 5

ER -

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: Increase in plasma TNFα levels during treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this